Continuous Versus Bolus Terlipressin for Acute Oesophageal Variceal Bleeding and Hepatorenal Syndrome in Cirrhosis: Meta-Analysis - PubMed
5 hours ago
- #Cirrhosis
- #Terlipressin
- #Meta-Analysis
- Continuous terlipressin infusion is compared to bolus infusion for treating acute oesophageal variceal bleeding (AEVB) and hepatorenal syndrome (HRS) in cirrhosis.
- Continuous infusion shows less treatment failure (RR, 0.32) and rebleeding (RR, 0.52) in AEVB, with a trend toward lower mortality.
- For HRS, response rates are comparable between continuous and bolus infusion (RR, 1.11).
- Continuous infusion reduces total adverse events (AEs) (RR, 0.59), including severe and cardiovascular AEs.
- A dose-response analysis suggests a correlation between drug dosage and cardiovascular AEs.
- A daily dose of 4–5 mg of terlipressin may offer the best balance between safety and effectiveness.